# US 9,517,232 B2 · Compounds for treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,232 B2
- Document ID: US9517232B2
- Status: Granted
- Kind: B2
- Application number: 14/854,928
- Filed: 2015-09-15
- Published: 2016-06-09
- Granted: 2016-12-13
- Earliest claimed: 2013-11-02
- Assignees: Medi Synergics, LLC
- Applicants: Dennis Michael Godek; Harry Ralph Howard
- Inventors: Dennis Michael Godek; Harry Ralph Howard
- Web page: https://patentgrep.com/patent/US9517232B2

## CPC

- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/351: not condensed with another ring
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 307/78: Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D 307/87: Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention is directed to the use of a compound of formula I, as defined herein, to a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing a compound of formula I, and to a combination of a compound of formula I with a pharmacologically effective cholinesterase inhibitor to treat a mammal, including a human, for a disorder or condition selected from the list including Alzheimer's disease, Huntington's disease, Parkinson's disease, non-Alzheimer's dementias and ALS.

## Claims

### Claim 1

A method of treating a disorder or condition, selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS and non-Alzheimer's dementias, comprising administering to a mammal in need of said treatment an effective amount of a compound of the formula I:
or the pharmaceutically acceptable salt(s) thereof.